K.V. Menshikov1,2, A.V. Sultanbaev1, S.I. Musin1, A.A. Izmaylov1,2, I.A. Menshikova2, A.F. Nasretdinov1, I.R. Shaykhutdinov2
1Republican Clinical Oncological Dispensary, Ufa
2Bashkir State Medical University, Ufa
Menshikov Konstantin V. ― Ph.D. (medicine), Associate Professor of the Department of Oncology with courses on oncology and pathological anatomy of the Bashkir State Medical University; oncologist of the Department of Chemotherapy of the Republican Clinical Oncological Dispensary
73/1 Oktyabrya Ave., Ufa, Russian Federation, 450054, tel. +7-917-348-82-51, e-mail: email@example.com, ORCID ID: 0000-0003-3734-2779
Goal of the analysis ― description of a clinical case of treatment of primary nonresectable hepatocellular cancer with two lines of therapy. The patient is treated with sorafenib and regorafenib in sequence.
Material and methods. The article presents a clinical case of treatment of advanced hepatocellular cancer. The patient receives treatment in Republican Clinical Oncological Dispensary (Ufa). The patient was diagnosed with nonresectable hepatocellular carcinoma, the diagnosis was verified morphologically. The patient received two lines of therapy ― sorafenib and regorafenib; the effectiveness of the therapy is assessed according to RECIST 1.1 criteria using PET CT and CT with bolus contrast. After registering the progression of the disease during therapy with sorafenib, the drug was changed to regorafenib. The assessment of the severity of adverse events is carried out according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Conclusion. The administration of target therapy with sorafenib and regorafenib consecutively for HCC not suitable for local regional therapy resulted in a stabilization that persisted for more than 20 months. From the first weeks of therapy, there was a favourable evolution in the patient's condition. The ability to work is restored, the patient actively engaged in daily activities. The therapy showed a satisfactory tolerance profile in a patient with comorbid pathology. Adverse events associated with therapy were short-term and did not affect the patient's quality of life, did not require withdrawal or dose reduction. The patient continues regorafenib therapy.
Key words: hepatocellular carcinoma, tyrosine kinase inhibitors, sorafenib, regorafenib.